Clinical Study

A Multicenter Phase 1/2B Study Of The Bruton’S Tyrosine Kinase Inhibitor, Ibrutinib (Pci-32765), In Combination With Carfilzomib (Kyprolis™) In Subjects With Relapsed Or Relapsed And Refractory Multiple Myeloma

Posted Date: Aug 2, 2017

  • Investigator: Saulius Girnius
  • Co-Investigator: Andrea Collins
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The study drug Ibrutinib (PCI-32765 or IMBRUVICA®) is a type of drug called a kinase inhibitor. Kinases are proteins that help cells live and grow. The specific kinase blocked by ibrutinib is believed to help blood cancer cells live and grow. By inhibi

Criteria:

To Be Eligible For This Study, Patients Must Have Multiple Myeloma

Keywords:

Pcyc-1119-Ca, Phase I, Cancer, Multiple Myeloma, Hematology

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Ride Cincinnati Gives $200,000 in Grants for Breast Cancer Research

    Marlene Harris-Ride Cincinnati has continued its support of UC Cancer Institutescientists with the annual award of five grants to continue promising breastcancer research.